Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Year: 2023
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: European Urology
Authors: Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, Manfred Wirth, Peter Staib, Martin Schostak, Philip Dargatz, Lothar Müller, Michael Metz, Lothar Bergmann, Thomas Steiner, Martin Welslau, Anja Lorch, Reza Rafiyan, Eva Hellmis, Cristopher Darr, Philipp Schütt, Johannes Meiler, Thomas Kretz, Wolfgang Loidl, Anne Flörcken, Martin Mänz, Axel Hinke, Arndt Hartmann, Carsten Grüllich
Institutions: Essen University Hospital, Medizinische Hochschule Hannover, University Hospital Heidelberg, University Hospital Carl Gustav Carus, Technische Universität Dresden, Sankt-Antonius-Hospital Eschweiler, University Hospital Magdeburg, Otto-von-Guericke-Universität Magdeburg, Johannes Wesling Klinikum Minden, University Hospital Frankfurt, Helios Klinikum Erfurt, Klinikum Aschaffenburg, Düsseldorf University Hospital, University Hospital Zurich, Krankenhaus Nordwest, Klinik Dr. Hancken, Charité – Universitätsmedizin Berlin, Universitätsklinikum Erlangen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Bristol-Myers Squibb
OpenAlex ID: W4387057579